Radiology and Nuclear Medicine, Amsterdam UMC Location AMC, Amsterdam, Noord-Holland, The Netherlands
Radiology and Nuclear Medicine, Amsterdam UMC Location AMC, Amsterdam, Noord-Holland, The Netherlands.
J Neurointerv Surg. 2023 Nov;15(e2):e262-e269. doi: 10.1136/jnis-2022-019569. Epub 2022 Nov 17.
Intravenous alteplase treatment (IVT) for acute ischemic stroke carries a risk of intracranial hemorrhage (ICH). However, reperfusion of an occluded vessel itself may contribute to the risk of ICH. We determined whether IVT and reperfusion are associated with ICH or its volume in the Multicenter Randomized Clinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN)-NO IV trial.
The MR CLEAN-NO IV trial randomized patients with acute ischemic stroke due to large vessel occlusion to receive either IVT followed by endovascular treatment (EVT) or EVT alone. ICH was classified according to the Heidelberg bleeding classification on follow-up MRI or CT approximately 8 hours-7 days after stroke. Hemorrhage volume was measured with ITK-snap. Successful reperfusion was defined as extended Thrombolysis In Cerebral Infarction (eTICI) score of 2b-3. Multinomial and binary adjusted logistic regression were used to determine the association of IVT and reperfusion with ICH subtypes.
Of 539 included patients, 173 (32%) developed ICH and 30 suffered from symptomatic ICH (sICH) (6%). Of the patients with ICH, 102 had hemorrhagic infarction, 47 had parenchymal hematoma, 44 had SAH, and six had other ICH. Reperfusion was associated with a decreased risk of SAH, and IVT was not associated with SAH (eTICI 2b-3: adjusted OR 0.45, 95% CI 0.21 to 0.97; EVT without IVT: OR 1.6, 95% CI 0.91 to 2.8). Reperfusion status and IVT were not associated with overall ICH, hemorrhage volume, and sICH (sICH: EVT without IVT, OR 0.96, 95% CI 0.41 to 2.25; eTICI 2b-3, OR 0.49, 95% CI 0.23 to 1.05).
Neither IVT administration before EVT nor successful reperfusion after EVT were associated with ICH, hemorrhage volume, and sICH. SAH occurred more often in patients for whom successful reperfusion was not achieved.
急性缺血性脑卒中的静脉内阿替普酶治疗(IVT)存在颅内出血(ICH)的风险。然而,闭塞血管的再灌注本身可能会增加 ICH 的风险。我们在荷兰多中心随机临床试验(MR CLEAN-NO IV 试验)中确定了 IVT 和再灌注是否与 ICH 或其体积有关。
MR CLEAN-NO IV 试验将因大血管闭塞而导致急性缺血性脑卒中的患者随机分为接受 IVT 后再进行血管内治疗(EVT)或单独 EVT 治疗。根据中风后 8 小时至 7 天的随访 MRI 或 CT,按照海德堡出血分类标准对 ICH 进行分类。使用 ITK-snap 测量出血体积。成功再灌注定义为扩展血栓溶解治疗脑梗死(eTICI)评分 2b-3。使用多项和二元调整逻辑回归来确定 IVT 和再灌注与 ICH 亚型的关系。
在 539 名纳入的患者中,173 名(32%)发生 ICH,30 名(6%)发生症状性 ICH(sICH)。ICH 患者中,102 名患有出血性梗死,47 名患有脑实质血肿,44 名患有蛛网膜下腔出血(SAH),6 名患有其他 ICH。再灌注与 SAH 风险降低相关,而 IVT 与 SAH 无关(eTICI 2b-3:调整后的 OR 0.45,95%CI 0.21 至 0.97;无 IVT 的 EVT:OR 1.6,95%CI 0.91 至 2.8)。再灌注状态和 IVT 与总体 ICH、出血体积和 sICH 无关(sICH:无 IVT 的 EVT,OR 0.96,95%CI 0.41 至 2.25;eTICI 2b-3,OR 0.49,95%CI 0.23 至 1.05)。
EVT 前的 IVT 给药或 EVT 后的成功再灌注均与 ICH、出血体积和 sICH 无关。未能实现成功再灌注的患者更常发生 SAH。